Company to deliver poster presentation regarding its
PARADIGM Phase 2b ALS study at
NEALS
CAMBRIDGE, Mass., Sept. 14,
2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
(NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for
severe neurodegenerative diseases, announced today it will
participate in the following ALS conferences.
3rd International Pan-Asian Consortium for
Treatment and Research in ALS (PACTALS) 2023
September 15-16, 2023
Kuala Lumpur, Malaysia
Attending: Dr. Ferenc Tracik, NeuroSense's Chief Medical
Officer
22nd Annual Northeast Amyotrophic Lateral Sclerosis
(NEALS) Meeting
October 4-6,
2023
Clearwater, Florida, U.S.
Attending: Dr. Shiran Zimri, NeuroSense's VP R&D
NeuroSense will deliver a poster presentation regarding PARADIGM
with a focus on the methodologies and biomarkers used in the Phase
2b study.
NeuroSense completed patient enrollment in PARADIGM for its
combination drug therapy, PrimeC, and expects to report topline
results in Q4 2023. The clinical trial endpoints include assessment
of ALS biomarkers, evaluation of clinical efficacy, and improvement
in quality of life to demonstrate an attenuation in disease
progression. Over 96% of participants who completed the trial chose
to continue in the study and be treated with PrimeC through a
12-month open-label extension.
About NeuroSense
NeuroSense Therapeutics, Ltd. is a
clinical-stage biotechnology company focused on discovering and
developing treatments for patients suffering from debilitating
neurodegenerative diseases. NeuroSense believes that these
diseases, which include amyotrophic lateral sclerosis (ALS),
Alzheimer's disease and Parkinson's disease, among others,
represent one of the most significant unmet medical needs of our
time, with limited effective therapeutic options available for
patients to date. Due to the complexity of neurodegenerative
diseases and based on strong scientific research on a large panel
of related biomarkers, NeuroSense's strategy is to develop combined
therapies targeting multiple pathways associated with these
diseases.
For additional information, we invite you to visit
our website and follow us
on LinkedIn and Twitter.
Forward-Looking Statements
This press release
contains "forward-looking statements" that are subject to
substantial risks and uncertainties. All statements, other than
statements of historical fact, contained in this press release are
forward-looking statements. Forward-looking statements contained in
this press release may be identified by the use of words such as
"anticipate," "believe," "contemplate," "could," "estimate,"
"expect," "intend," "seek," "may," "might," "plan," "potential,"
"predict," "project," "target," "aim," "should," "will" "would," or
the negative of these words or other similar expressions, although
not all forward-looking statements contain these words.
Forward-looking statements are based on NeuroSense Therapeutics'
current expectations and are subject to inherent uncertainties,
risks and assumptions that are difficult to predict and include
statements regarding the timing of top-line results of, and the
results of, the PARADIGM clinical trial. Further, forward-looking
statements are subject to a number of risks and uncertainties as a
result of which actual results could differ materially and
adversely from those anticipated or implied in the forward looking
statements. These risks include a delay in the reporting of
top-line results from PARADIGM clinical trial; greater than
anticipated costs and expenses; the potential for PrimeC to safely
and effectively target ALS; preclinical and clinical data for
PrimeC; the timing of current and future clinical trials, timing
for reporting data; the nature, strategy and focus of the company
and further updates with respect thereto; the development and
commercial potential of any product candidates of the company; and
other risks and uncertainties set forth in NeuroSense's filings
with the Securities and Exchange Commission (SEC), including
NeuroSense's Annual Report on Form 20-F filed with the SEC on
March 22, 2023. Forward-looking
statements contained in this announcement are made as of this date,
and NeuroSense Therapeutics Ltd. undertakes no duty to update such
information except as required under applicable law.
Logo:
https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/neurosense-to-participate-in-upcoming-als-conferences-pactals-in-malaysia-and-neals-in-the-us-301927714.html
SOURCE NeuroSense